Baudelet Davy, Lipka Emmanuelle, Millet Régis, Ghinet Alina
INSERM, U995, LIRIC, Universite Lille 2, CHRU de Lille, Faculte de Medecine - Pole Recherche, Place Verdun, F-59045 Lille Cedex, France.
Curr Med Chem. 2015;22(6):713-29. doi: 10.2174/0929867322666141212120926.
The purinergic receptor P2X7 is highly expressed in immune peripheral and central cells suggesting its important role in numerous diseases characterized by inflammatory processes like cancer, or neurodegenerative pathologies in relation with modulation of the immune system. Thereby, antagonization of this receptor may be a hopeful therapeutic strategy to treat a large range of diseases. Indeed, selective P2X7 antagonists display beneficial anti-inflammatory, analgesic, and in some cases, anticancer properties. This article will review the involvement of P2X7 in the immune system, the update of P2X7 antagonists series since 2009 and their promising therapeutic potential for the treatment of several immune- related diseases.
嘌呤能受体P2X7在免疫外周细胞和中枢细胞中高度表达，这表明它在许多以炎症过程为特征的疾病中发挥重要作用，如癌症，或与免疫系统调节相关的神经退行性疾病。因此，拮抗该受体可能是治疗多种疾病的一种有前景的治疗策略。事实上，选择性P2X7拮抗剂具有有益的抗炎、镇痛作用，在某些情况下还具有抗癌特性。本文将综述P2X7在免疫系统中的作用、自2009年以来P2X7拮抗剂系列的进展及其在治疗几种免疫相关疾病方面的潜在治疗前景。
